First-Line Encorafenib and Cetuximab + FOLFIRI Improves Outcomes Over FOLFIRI and Bevacizumab in BRAF-Mutant mCRC
Abstract
The BREAKWATER trial previously demonstrated that encorafenib and cetuximab plus modified FOLFOX6 offers significant benefit in BRAFV600E-mutant metastatic colorectal cancer and received accelerated FDA approval. A new analysis showed that encorafenib and cetuximab plus FOLFIRI yields a significant and clinically meaningful benefit compared with FOLFIRI and bevacizumab as first-line treatment in this patient population (Abstract 13).
Fields of Study & Subjects
Colorectal Cancer Treatments and Studies
Colorectal Cancer Surgical Treatments
Lung Cancer Treatments and Mutations
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 10 January 2026
- Document type
- Dataset